E-LIB Suche - Ergebnisse für: Heerspink, H

1

TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIA..:

Heerspink, H. ; Tuttle, K. ; Pavo, I....
Canadian Journal of Diabetes. 47 (2023) 7 - p. S114 , 2023

Link: https://doi.org/10.1016/..

2

WCN23-1087 SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH ..:

Wong, M.G. ; Heerspink, H.J. ; Komers, R...
Kidney International Reports. 8 (2023) 3 - p. S126-S127 , 2023

Link: https://doi.org/10.1016/..

3

TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIA..:

Heerspink, H. ; Tuttle, K. ; Pavo, I....
Canadian Journal of Cardiology. 39 (2023) 10 - p. S144 , 2023

Link: https://doi.org/10.1016/..

4

[18F]FDG and [18F]NaF as PET markers of systemic atheroscle..:

Reijrink, M. ; de Boer, S.A. ; te Velde-Keyzer, C.A....
Journal of Nuclear Cardiology. 29 (2022) 4 - p. 1702-1709 , 2022

Link: https://doi.org/10.1007/..

5

Effects of dapagliflozin on cardiovascular and kidney event..:

Moura, F ; Wiviott, S ; Chertow, G...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

6

POS-322 Association of Changes in Modifiable Factors with C..:

Nadkarni, G. ; Takale, D. ; Chauhan, K....
Kidney International Reports. 7 (2022) 2 - p. S145 , 2022

Link: https://doi.org/10.1016/..

7

IDF21-0197 Take CaRe of Me Programme: Gaps in early diagnos..:

Joshi, S. ; Fenici, P. ; Heerspink, H....
Diabetes Research and Clinical Practice. 186 (2022) - p. 109259 , 2022

Link: https://doi.org/10.1016/..

8

POS-327 THE COST OF END OF LIFE INPATIENT ENCOUNTERS IN PAT..:

ARNOLD, M. ; Garcia Sanchez, J.J. ; Carrero, J.J....
Kidney International Reports. 6 (2021) 4 - p. S141 , 2021

Link: https://doi.org/10.1016/..

9

Effects of canagliflozin on hyperkalaemia and serum potassi..:

Neuen, B L ; Oshima, M ; Perkovic, V...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

10

POS-223 Clinical Utility of KidneyIntelX in Patients with E..:

Lam, D. ; Nadkarni, G. ; Neal, B....
Kidney International Reports. 6 (2021) 4 - p. S93-S94 , 2021

Link: https://doi.org/10.1016/..

11

PUK4 General Practitioner Utilization and Costs of Chronic ..:

Garcia Sanchez, J.J. ; Arnold, M. ; Carrero, J.J....
Value in Health. 24 (2021) - p. S234 , 2021

Link: https://doi.org/10.1016/..

12

POS-503 EVALUATING CHRONIC KIDNEY DISEASE PROGRESSION: A RE..:

ABDUL SULTAN, A. ; Heerspink, H. ; Arnold, M....
Kidney International Reports. 6 (2021) 4 - p. S218-S219 , 2021

Link: https://doi.org/10.1016/..

13

POS-335 COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS A TREATMENT ..:

MCEWAN, P. ; Darlington, O. ; Wheeler, D....
Kidney International Reports. 6 (2021) 4 - p. S145-S146 , 2021

Link: https://doi.org/10.1016/..

14

POS-319 EMERGENCY AND CRITICAL HEALTHCARE RESOURCE UTILISAT..:

GARCIA SANCHEZ, J.J. ; Carrero, J.J. ; Arnold, M....
Kidney International Reports. 6 (2021) 4 - p. S137 , 2021

Link: https://doi.org/10.1016/..

15

POS-336 THE IMPACT OF CHRONIC KIDNEY DISEASE AND CLINICAL E..:

MCEWAN, P. ; Darlington, O. ; Garcia-Sanchez, J....
Kidney International Reports. 6 (2021) 4 - p. S146 , 2021

Link: https://doi.org/10.1016/..